Sakar Healthcare Ltd

Sakar Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sakar Healthcare Ltd

₹ 326 -0.67%
14 Aug - close price
Company website NSE: SAKAR
About

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]

Key Points

Business Overview:[1][2][3]
SHL, certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and the National Drug Authority, provides comprehensive healthcare and pharmaceutical products. Operating in over 50 countries with 292 registered products and 210 more under registration, SHL partners with 70+ overseas distributors. The company also engages in contract manufacturing for leading domestic brands and direct sales in both domestic and export markets.

Website NSE - BE
  • Market Cap ₹ 715 Cr.
  • Current Price ₹ 326
  • High / Low ₹ 381 / 210
  • Stock P/E 36.1
  • Book Value ₹ 130
  • Dividend Yield 0.00 %
  • ROCE 8.58 %
  • ROE 6.40 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 2.50 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -0.72%
  • Company has a low return on equity of 6.51% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
28.53 30.71 33.47 40.65 38.99 34.08 37.23 43.06 41.15 42.78 43.42 50.24 52.74
20.57 22.12 24.67 32.87 29.96 24.72 28.22 32.09 30.45 31.28 31.66 34.52 40.03
Operating Profit 7.96 8.59 8.80 7.78 9.03 9.36 9.01 10.97 10.70 11.50 11.76 15.72 12.71
OPM % 27.90% 27.97% 26.29% 19.14% 23.16% 27.46% 24.20% 25.48% 26.00% 26.88% 27.08% 31.29% 24.10%
0.41 0.60 1.85 1.81 1.52 0.66 0.23 0.77 0.46 0.37 0.25 0.18 0.39
Interest 0.86 0.99 1.94 2.15 2.08 1.65 1.79 2.08 1.40 1.64 1.30 4.19 2.14
Depreciation 3.57 3.77 4.10 3.55 4.52 4.22 4.44 4.87 5.06 5.12 5.23 5.48 5.57
Profit before tax 3.94 4.43 4.61 3.89 3.95 4.15 3.01 4.79 4.70 5.11 5.48 6.23 5.39
Tax % 26.90% 56.21% 13.02% -0.77% 28.10% 12.53% 30.90% 34.86% 48.72% 6.07% 17.15% 7.70% 13.17%
2.88 1.94 4.01 3.92 2.84 3.64 2.07 3.12 2.41 4.80 4.53 5.76 4.67
EPS in Rs 1.68 1.04 2.15 2.06 1.49 1.70 0.95 1.43 1.11 2.21 2.06 2.62 2.13
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
83 95 128 133 153 178 189
63 72 99 100 115 128 137
Operating Profit 20 23 29 33 38 50 52
OPM % 24% 24% 23% 25% 25% 28% 27%
2 1 2 5 3 1 1
Interest 2 2 3 6 8 9 9
Depreciation 7 8 10 15 18 21 21
Profit before tax 12 13 19 17 16 22 22
Tax % 21% 19% 20% 24% 27% 19%
10 11 15 13 12 18 20
EPS in Rs 6.43 6.84 8.90 6.70 5.37 7.97 9.02
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 16%
3 Years: 11%
TTM: 22%
Compounded Profit Growth
10 Years: %
5 Years: 13%
3 Years: 5%
TTM: 76%
Stock Price CAGR
10 Years: %
5 Years: 37%
3 Years: 23%
1 Year: 4%
Return on Equity
10 Years: %
5 Years: 8%
3 Years: 7%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 15 16 17 19 22 22
Reserves 66 83 110 154 241 264
17 43 93 119 79 75
17 37 47 44 47 55
Total Liabilities 115 178 268 336 389 415
66 69 205 267 314 309
CWIP 13 49 1 6 0 17
Investments 0 0 7 3 0 0
36 60 55 60 74 90
Total Assets 115 178 268 336 389 415

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
19 15 36 33 24 34
-22 -47 -90 -74 -52 -31
3 32 55 41 27 -3
Net Cash Flow -0 -0 -0 0 0 -0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 36 48 40 60 50 63
Inventory Days 93 112 69 76 121 193
Days Payable 46 141 149 129 120 93
Cash Conversion Cycle 83 19 -39 7 51 163
Working Capital Days 31 1 -11 -6 29 52
ROCE % 13% 12% 9% 7% 9%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
62.10% 62.10% 60.72% 60.72% 54.15% 53.15% 53.15% 53.15% 53.15% 53.58% 53.58% 52.86%
16.12% 16.12% 15.74% 15.74% 14.03% 13.76% 13.52% 13.52% 13.42% 13.58% 13.61% 13.41%
0.55% 0.33% 0.00% 0.00% 10.82% 10.62% 10.62% 10.62% 10.62% 10.88% 10.97% 11.25%
21.24% 21.45% 23.54% 23.54% 21.00% 22.47% 22.71% 22.71% 22.80% 21.96% 21.85% 22.48%
No. of Shareholders 5,6786,2106,3226,0567,2997,0017,3867,3137,8678,5988,6088,115

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • Oct 2022
    Transcript
    Notes
    PPT
  • Dec 2018
    Transcript
    Notes
    PPT